Cyclin D as a therapeutic target in cancer
The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Abstract
Cyclin D1, and to a lesser extent the other D-type cyclins, is frequently deregulated in cancer and is a biomarker of cancer phenotype and disease progression. The ability of these cyclins to activate the cyclin-dependent kinases (CDKs) CDK4 and CDK6 is the most extensively documented mechanism for their oncogenic actions and provides an attractive therapeutic target. Is this an effective means of targeting the cyclin D oncogenes, and how might the patient subgroups that are most likely to benefit be identified?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Failure to modify cyclin D1 on T286 leads to aberrant nuclear accumulation of the protein, premature S phase entry, and enhanced cellular proliferation that drives tumorigenesis (17).”
From A genome-wide screen reveals that Dyrk1A kinase promotes nucleotide excision repair by preventing aberrant overexpression of cyclin D1 and p21 (2023) · cites this paper as [17]
In the citing paper
“Possibly, CCND1 amplification and CDKN2A loss may contribute to determining response to letrozole alone”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [68]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“The deregulation of cyclin expression or CDK activation can directly lead to some of the hallmarks of cance”
BackgroundComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115 · cited 1×
“A second well-described non-catalytic role of cyclin D is the sequestration of p21 and p27 by cyclin D–CDK4/CDK6, leading to the indirect activation of CDK2 (REF”
BackgroundIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“It may also be possible to identify low-molecular-mass inhibitors of cyclin–CDK substrate interactions using high-throughput screens that are similar to those used for the discovery and preclinical testing of inhibitors of MDM2–p53 binding (nutlins”
MethodThe landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“by causing proliferation that is independent of normal extracellular cues, or by over-riding checkpoints that ensure genomic integrity and stabilit”
BackgroundFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387 · cited 1×
“Given the increasingly routine clinical use of specific kinase inhibitor”
BackgroundmTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322 · cited 1×
“In Phase II clinical trials mTOR inhibitors were particularly effective in MCL, which is characterized by almost universal overexpression of cyclin D1, although this may not be accompanied by a reduction in cyclin D1 expression (reviewed in REF”
BackgroundBiological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
Self-citationFry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
CDK inhibitors: Cell cycle regulators and beyond
Besson, A., Dowdy, S. F., & Roberts, J. M. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.01.013 · Cited by 1,152 · cited 1×
“The synthesis of individual cyclins, and consequent cyclin-dependent kinase (CDK) activation at specific cell cycle stages, coordinates the sequential completion of DNA replication and cell divisio”
BackgroundLiving with or without cyclins and cyclin-dependent kinases
Sherr, C. J., & Roberts, J. M. (2004) · Genes & Development · doi:10.1101/gad.1256504 · Cited by 1,089 · cited 1×
“The synthesis of individual cyclins, and consequent cyclin-dependent kinase (CDK) activation at specific cell cycle stages, coordinates the sequential completion of DNA replication and cell divisio”
BackgroundCyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036 · cited 1×
“Early evidence of the high incidence of aberrant cyclin expression in myriad cancer types and the sensitivity of cancer cells to acute inhibition of cyclins or CDKs, including cyclin D1, led to programmes that aimed to develop small-molecule CDK inhibitors as therapeutic”
BackgroundEmerging roles of E2Fs in cancer: an exit from cell cycle control
Chen, H.-Z., Tsai, S.-Y., & Leone, G. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2696 · Cited by 1,021 · cited 1×
“The simple model in which RB phosphorylation by CDKs, including cyclin D–CDK4/CDK6, promotes the activation of E2F-responsive genes that are necessary for DNA synthesis has subsequently been elaborated to take into account factors such as combinatorial interactions between RB family proteins and various members of the…”
BackgroundThe miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities
Bonci, D., Coppola, V., Musumeci, M., Addario, A., Giuffrida, R., Memeo, L., D'Urso, L., Pagliuca, A., Biffoni, M., Labbaye, C., et al. (2008) · Nature Medicine · doi:10.1038/nm.1880 · Cited by 989 · cited 1×
“Their expression is inversely correlated with cyclin D1 expression in the small series of prostate and lung cancers that have been examined to dat”
BackgroundMinireview: Cyclin D1: Normal and Abnormal Functions
Fu, M., Wang, C., Li, Z., Sakamaki, T., & Pestell, R. G. (2004) · Endocrinology · doi:10.1210/en.2004-0959 · Cited by 966
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnold, A., & Schmidt, E. V. (1994) · Nature · doi:10.1038/369669a0 · Cited by 965
Specific protection against breast cancers by cyclin D1 ablation
Yu, Q., Geng, Y., & Sicinski, P. (2001) · Nature · doi:10.1038/35082500 · Cited by 934 · cited 1×
“Cells lacking all three D-type cyclins are resistant to transformation by various oncogenes in vitro , and mice lacking cyclin D1 are resistant to the effects of some, although not all, mammary oncogene”
BackgroundRosenwald, A., Wright, G., Wiestner, A., Chan, W. C., Connors, J. M., Campo, E., Gascoyne, R. D., Grogan, T. M., Muller-Hermelink, H. K., Smeland, E. B., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00028-x · Cited by 914 · cited 1×
“In MCL CCND1 mRNA expression correlates with a proliferation signature that is comprised of genes that are expressed at higher levels in dividing cells than in quiescent cells, with the highest levels of proliferation or cyclin D1 expression associated with the poorest overall surviva”
BackgroundCell cycle kinases as therapeutic targets for cancer
Lapenna, S., & Giordano, A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2907 · Cited by 905 · cited 1×
“Early evidence of the high incidence of aberrant cyclin expression in myriad cancer types and the sensitivity of cancer cells to acute inhibition of cyclins or CDKs, including cyclin D1, led to programmes that aimed to develop small-molecule CDK inhibitors as therapeutic”
BackgroundMatsushime, H., Ewen, M. E., Strom, D. K., Kato, J.-Y., Hanks, S. K., Roussel, M. F., & Sherr, C. J. (1992) · Cell · doi:10.1016/0092-8674(92)90360-o · Cited by 897 · cited 1×
“They activate CDK4 and CDK6, which are phylogenetically distinct from the canonical CDKs, CDK1 and CDK2, and have different substrate specificit”
BackgroundThe BATTLE Trial: Personalizing Therapy for Lung Cancer
Kim, E. S., Herbst, R. S., Wistuba, I. I., Lee, J. J., Blumenschein, G. R., Tsao, A., Stewart, D. J., Hicks, M. E., Erasmus, J., Gupta, S., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0010 · Cited by 889
Alao, J. P. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-24 · Cited by 871
Regulation of the INK4b–ARF–INK4a tumour suppressor locus: all for one or one for all
Gil, J., & Peters, G. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1987 · Cited by 843 · cited 1×
“The specific inhibition of cyclin D–CDK4/CDK6 through the induction of INK4A promotes RB-dependent cell cycle arrest in some circumstances, such as during senescenc”
BackgroundIdentification of G1 kinase activity for cdk6, a novel cyclin D partner.
Meyerson, M., & Harlow, E. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.2077 · Cited by 794
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793
CDK-Independent Activation of Estrogen Receptor by Cyclin D1
Zwijsen, R. M. L., Wientjens, E., Klompmaker, R., van der Sman, J., Bernards, R., & Michalides, R. J. A. M. (1997) · Cell · doi:10.1016/s0092-8674(00)81879-6 · Cited by 720
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
Weinstein, I. B., & Joe, A. K. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0558 · Cited by 705 · cited 1×
“Targeting cyclin D as therapy for cancer Oncoproteins are attractive therapeutic targets as they are causally related to cancer development, and cancer cells often become dependent on them for continued proliferation and survival ( oncogene addiction”
BackgroundMouse development and cell proliferation in the absence of D-cyclins
Kozar, K., Ciemerych, M. A., Rebel, V. I., Shigematsu, H., Zagozdzon, A., Sicinska, E., Geng, Y., Yu, Q., Bhattacharya, S., Bronson, R. T., et al. (2004) · Cell · doi:10.1016/j.cell.2004.07.025 · Cited by 647 · cited 1×
“Many of the non-catalytic effects of the D-type cyclins have been elucidated using cell culture models, and simultaneous knockout of all three D-type cyclins has a very similar phenotype to knockout of both Cdk4 and Cdk6 (REF”
BackgroundMolecular Pathogenesis and a Consequent Classification of Multiple Myeloma
Bergsagel, P. L., & Kuehl, W. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.021 · Cited by 556
Cyclin-dependent kinases regulate the antiproliferative function of Smads
Matsuura, I., Denissova, N. G., Wang, G., He, D., Long, J., & Liu, F. (2004) · Nature · doi:10.1038/nature02650 · Cited by 503 · cited 2×
“CCND1: IGH translocation t(11;14)(q13;q32) Multiple myeloma 16% 185”
BackgroundA census of amplified and overexpressed human cancer genes
Santarius, T., Shipley, J., Brewer, D., Stratton, M. R., & Cooper, C. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2771 · Cited by 482 · cited 1×
“Cyclin D overexpression in cancer CCND1 is a well-established human oncogene: a recent census concluded that there was substantial evidence for the involvement of CCND1 amplification and overexpression in breast cancer and significant evidence for its involvement in lung cancer, melanoma and oral squamous cell carcino…”
BackgroundJares, P., Colomer, D., & Campo, E. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2230 · Cited by 466 · cited 1×
“Although MCL is distinguished by almost universal overexpression of cyclin D1, concomitant deletions of the CDKN2A locus (encoding INK4A and ARF), CDK4 amplification or microdeletions in RB1 leading to loss of RB protein expression, also occur and are associated with more proliferative, aggressive diseas”
BackgroundLinking cyclins to transcriptional control
Coqueret, O. (2002) · Gene · doi:10.1016/s0378-1119(02)01055-7 · Cited by 431
Requirement for CDK4 kinase function in breast cancer
Yu, Q., Sicinska, E., Geng, Y., Ahnström, M., Zagozdzon, A., Kong, Y., Gardner, H., Kiyokawa, H., Harris, L. N., Stål, O., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.012 · Cited by 429 · cited 1×
“The CDK activation function of cyclin D1 is largely dispensible during mammary development, but it is required for mammary oncogenesis, as mice lacking cyclin D1 or CDK4, or expressing the CDK4/CDK6-specific inhibitor INK4A or the cyclin D1 K112E mutant, are resistant to mammary cancers induced by ERBB2 (also known as…”
BackgroundA Mechanism of Cyclin D1 Action Encoded in the Patterns of Gene Expression in Human Cancer
Lamb, J., Ramaswamy, S., Ford, H. L., Contreras, B., Martinez, R. V., Kittrell, F. S., Zahnow, C. A., Patterson, N., Golub, T. R., & Ewen, M. E. (2003) · Cell · doi:10.1016/s0092-8674(03)00570-1 · Cited by 416 · cited 1×
“However, in a large panel of different cancers there was no correlation between cyclin D1 expression and a signature of genes responsive to E2F1 and E2F2 (REF”
BackgroundPuyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415 · cited 1×
“KRAS-driven non-small-cell lung cancer is particularly dependent on CDK4, but not on CDK2 (REF”
BackgroundNuclear cyclin D1: an oncogenic driver in human cancer
Kim, J. K., & Diehl, J. A. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21791 · Cited by 413 · cited 1×
“Cancer-associated mutations in cyclin D1 that lead to constitutive nuclear localization and impaired degradation increase the transforming activity of cyclin D1 in cell culture and reduce the latency of cyclin D1-driven tumour development in animal model”
BackgroundCyclin D1 in Breast Cancer Pathogenesis
Arnold, A., & Papanikolaou, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.064 · Cited by 411 · cited 1×
“However, it is also possible that some of the non-catalytic functions of cyclin D1 contribute to its role in human cance”
BackgroundTargeted Disruption of CDK4 Delays Cell Cycle Entry with Enhanced p27 Kip1 Activity
Tsutsui, T., Hesabi, B., Moons, D. S., Pandolfi, P. P., Hansel, K. S., Koff, A., & Kiyokawa, H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.10.7011 · Cited by 395
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
Dean, J. L., Thangavel, C., McClendon, A. K., Reed, C. A., & Knudsen, E. S. (2010) · Oncogene · doi:10.1038/onc.2010.154 · Cited by 393 · cited 1×
“In vitro resistance to long-term treatment with a CDK4/CDK6-specific inhibitor is associated with increased CDK2 activity in both breast cancer and acute myeloid leukaemia (AML) cell line”
BackgroundCyclin D1 Stimulation of Estrogen Receptor Transcriptional Activity Independent of cdk4†
Neuman, E., Ladha, M. H., Lin, N., Upton, T. M., Miller, S. J., DiRenzo, J., Pestell, R. G., Hinds, P. W., Dowdy, S. F., Brown, M., et al. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.9.5338 · Cited by 392
Bandi, N., Zbinden, S., Gugger, M., Arnold, M., Kocher, V., Hasan, L., Kappeler, A., Brunner, T., & Vassella, E. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4277 · Cited by 386 · cited 1×
“Their expression is inversely correlated with cyclin D1 expression in the small series of prostate and lung cancers that have been examined to dat”
BackgroundAdams, P. D., Sellers, W. R., Sharma, S. K., Wu, A. D., Nalin, C. M., & Kaelin, W. G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.6623 · Cited by 373
Lukas, J., Bartkova, J., Rohde, M., Strauss, M., & Bartek, J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.5.2600 · Cited by 366
Cyclin D1: polymorphism, aberrant splicing and cancer risk
Knudsen, K. E., Diehl, J. A., Haiman, C. A., & Knudsen, E. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209371 · Cited by 363
Lee, R. J., Albanese, C., Fu, M., D'Amico, M., Lin, B., Watanabe, G., Haines, G. K., Siegel, P. M., Hung, M.-C., Yarden, Y., et al. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.2.672-683.2000 · Cited by 347 · cited 1×
“ERBB2-driven or RAS-driven mammary cancers in mice express high levels of cyclin D1 (REF”
BackgroundTailoring to RB: tumour suppressor status and therapeutic response
Knudsen, E. S., & Knudsen, K. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2401 · Cited by 344 · cited 1×
“Like cyclin D1 overexpression, RB loss does not have a clear-cut association with patient outcom”
BackgroundRequirement for cyclin D3 in lymphocyte development and T cell leukemias
Sicinska, E., Aifantis, I., Le Cam, L., Swat, W., Borowski, C., Yu, Q., Ferrando, A. A., Levin, S. D., Geng, Y., von Boehmer, H., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00301-5 · Cited by 340 · cited 1×
“The targeted deletion of either Cdk6 or Ccnd3 causes resistance to lymphoma genesi”
BackgroundA function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers
Jirawatnotai, S., Hu, Y., Michowski, W., Elias, J. E., Becks, L., Bienvenu, F., Zagozdzon, A., Goswami, T., Wang, Y. E., Clark, A. B., et al. (2011) · Nature · doi:10.1038/nature10155 · Cited by 333
Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis
Landis, M. W., Pawlyk, B. S., Li, T., Sicinski, P., & Hinds, P. W. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.019 · Cited by 329 · cited 1×
“However, defects in retinal and mammary gland development in mice lacking Ccnd1 are largely restored when the K112E cyclin D1 point mutant is knocked in to the Ccnd1 locu”
BackgroundMichaud, K., Solomon, D. A., Oermann, E., Kim, J.-S., Zhong, W.-Z., Prados, M. D., Ozawa, T., James, C. D., & Waldman, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4559 · Cited by 319
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas
Smalley, K. S. M., Lioni, M., Palma, M. D., Xiao, M., Desai, B., Egyhazi, S., Hansson, J., Wu, H., King, A. J., Van Belle, P., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0431 · Cited by 309
Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1
Zwijsen, R. M. L., Buckle, R. S., Hijmans, E. M., Loomans, C. J. M., & Bernards, R. (1998) · Genes & Development · doi:10.1101/gad.12.22.3488 · Cited by 305
Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
Konecny, G. E., Winterhoff, B., Kolarova, T., Qi, J., Manivong, K., Dering, J., Yang, G., Chalukya, M., Wang, H.-J., Anderson, L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2307 · Cited by 302
Fu, M., Rao, M., Bouras, T., Wang, C., Wu, K., Zhang, X., Li, Z., Yao, T.-P., & Pestell, R. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500403200 · Cited by 276
Transcriptional role of cyclin D1 in development revealed by a genetic-proteomic screen
Bienvenu, F., Jirawatnotai, S., Elias, J. E., Meyer, C. A., Mizeracka, K., Marson, A., Frampton, G. M., Cole, M. F., Odom, D. T., Odajima, J., et al. (2010) · Nature · doi:10.1038/nature08684 · Cited by 276 · cited 1×
“Cyclin D1 is tethered to the promoters of many genes during normal development, probably through interactions with various transcription factor”
BackgroundLukas, J., Müller, H., Bartkova, J., Spitkovsky, D., Kjerulff, A. A., Jansen-Dürr, P., Strauss, M., & Bartek, J. (1994) · The Journal of cell biology · doi:10.1083/jcb.125.3.625 · Cited by 269 · cited 1×
“Evidence that cyclin D1 is not necessary for proliferation in cultured cells in the absence of functional RB suggested that RB is the principal substrate for cyclin D1–CDK4, and presumably for other cyclin D-associated CDK”
BackgroundSchwartz, G. K., LoRusso, P. M., Dickson, M. A., Randolph, S. S., Shaik, M. N., Wilner, K. D., Courtney, R., & O'Dwyer, P. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.177 · Cited by 260
Molecular prognostic markers in pancreatic cancer: A systematic review
Garcea, G., Neal, C. P., Pattenden, C. J., Steward, W. P., & Berry, D. P. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.044 · Cited by 259
Wiestner, A., Tehrani, M., Chiorazzi, M., Wright, G., Gibellini, F., Nakayama, K., Liu, H., Rosenwald, A., Muller-Hermelink, H. K., Ott, G., et al. (2007) · Blood · doi:10.1182/blood-2006-08-039859 · Cited by 252 · cited 1×
“Mutations in the 3′ untranslated region that result in the stabilization of the CCND1 mRNA have been reported in MC”
BackgroundEvron, E., Umbricht, C. B., Korz, D., Raman, V., Loeb, D. M., Niranjan, B., Buluwela, L., Weitzman, S. A., Marks, J. R., & Sukumar, S. V. (2001) · PubMed · Cited by 249
Kenny, F. S., Hui, R., Musgrove, E. A., Gee, J. M. W., Blamey, R. W., Nicholson, R. I., Sutherland, R. L., & Robertson, J. F. R. (1999) · PubMed · Cited by 245
Self-citationCyclin D1 in non-small cell lung cancer: A key driver of malignant transformation
Gautschi, O., Ratschiller, D., Gugger, M., Betticher, D. C., & Heighway, J. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2006.09.024 · Cited by 243 · cited 1×
“However, in some cancers, such as lung, prostate and ovarian cancer, overexpressed cyclin D1 is exclusively cytoplasmic in a significant proportion of case”
BackgroundAggarwal, P., Vaites, L. P., Kim, J. K., Mellert, H., Gurung, B., Nakagawa, H., Herlyn, M., Hua, X., Rustgi, A. K., McMahon, S. B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.012 · Cited by 242 · cited 1×
“and ribosome biogenesis (through phosphorylation of MEP50, a co-activator of the arginine methyltransferase PRMT5, which in turn methylates ribosome proteins”
BackgroundRoberts, P. J., Stinchcombe, T. E., Der, C. J., & Socinski, M. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4365 · Cited by 240
Crystal structure of human CDK4 in complex with a D-type cyclin
Day, P. J., Cleasby, A., Tickle, I. J., O'Reilly, M., Coyle, J. E., Holding, F. P., McMenamin, R. L., Yon, J., Chopra, R., Lengauer, C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809645106 · Cited by 232
Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue.
Bova, R., Quinn, D. I., Nankervis, J., Cole, I. E., Sheridan, B. F., Jensen, M. R., Morgan, G. J., Hughes, C. J., & Sutherland, R. L. (1999) · PubMed · Cited by 229
Self-citationSuppression of Cancer Cell Growth by Promoting Cyclin D1 Degradation
Shan, J., Zhao, W., & Gu, W. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.10.018 · Cited by 229 · cited 1×
“Promoting cyclin D1 degradation by knockdown of USP2, a deubiquitylating enzyme that specifically targets cyclin D1, inhibited proliferation in cancer cells overexpressing cyclin D1 but not in normal fibroblasts, suggesting that targeting cyclin D1 degradation through this mechanism could be an effective, cancer-speci…”
BackgroundBaughn, L. B., Di Liberto, M., Wu, K., Toogood, P. L., Louie, T., Gottschalk, R., Niesvizky, R., Cho, H., Ely, S., Moore, M. A. S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1098 · Cited by 225 · cited 1×
“CDK4/CDK6 inhibitors may also lead to enhanced efficacy when used in combination with other therapies — for example, the proteasome inhibitor bortezomib or dexamethasone in multiple myelom”
BackgroundPattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
Wiedemeyer, W. R., Dunn, I. F., Quayle, S. N., Zhang, J., Chheda, M. G., Dunn, G. P., Zhuang, L., Rosenbluh, J., Chen, S., Xiao, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001613107 · Cited by 223
Arris, C. E., Boyle, F. T., Calvert, A. H., Curtin, N. J., Endicott, J. A., Garman, E. F., Gibson, A. E., Golding, B. T., Grant, S., Griffin, R. J., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990628o · Cited by 215
Roy, P. G., & Thompson, A. M. (2006) · The Breast · doi:10.1016/j.breast.2006.02.005 · Cited by 210
Wang, C., Li, Z., Lu, Y., Du, R., Katiyar, S., Yang, J., Fu, M., Leader, J. E., Quong, A., Novikoff, P. M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603363103 · Cited by 208
Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma
Thomas, G. R., Nadiminti, H., & Regalado, J. (2005) · International Journal of Experimental Pathology · doi:10.1111/j.0959-9673.2005.00447.x · Cited by 204
Initiating oncogenic event determines gene-expression patterns of human breast cancer models
Desai, K. V., Xiao, N., Wang, W., Gangi, L., Greene, J., Powell, J. I., Dickson, R., Furth, P., Hunter, K., Kucherlapati, R., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.102172399 · Cited by 196
Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance
Taneja, P., Maglic, D., Kai, F., Zhu, S., Kendig, R. D., Elizabeth, A., & Inoue, K. (2010) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s4773 · Cited by 196
Knudsen, K. E., Cavenee, W. K., & Arden, K. C. (1999) · PubMed · Cited by 191
Reutens, A. T. (2001) · Molecular Endocrinology · doi:10.1210/me.15.5.797 · Cited by 189
Regulation of the cytoskeleton: an oncogenic function for cdk inhibitors?
Besson, A., Assoian, R. K., & Roberts, J. M. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1501 · Cited by 189 · cited 1×
“, and p27 has CDK-independent effects on cell migration through RHOA and stathmi”
BackgroundMolecular pathogenesis of head and neck squamous cell carcinoma
Hardisson, D. (2003) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-003-0581-3 · Cited by 186
Cyclin D1 Determines Mitochondrial Function InVivo
Sakamaki, T., Casimiro, M. C., Ju, X., Quong, A. A., Katiyar, S., Liu, M., Jiao, X., Li, A., Zhang, X., Lu, Y., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02074-05 · Cited by 183
Biliran, H., Wang, Y., Banerjee, S., Xu, H., Heng, H., Thakur, A., Bollig, A., Sarkar, F. H., & Liao, J. D. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2419 · Cited by 181
Cyclin D1Governs Adhesion and Motility of Macrophages
Neumeister, P., Pixley, F. J., Xiong, Y., Xie, H., Wu, K., Ashton, A. W., Cammer, M., Chan, A. Y., Symons, M. H., Stanley, E. R., et al. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.02-07-0102 · Cited by 179 · cited 1×
“Fibroblasts, epithelial cells and macrophages have increased adhesion and reduced migration in the absence of cyclin D1 (REF”
BackgroundP/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor
McMahon, C., Suthiphongchai, T., DiRenzo, J., & Ewen, M. E. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5382 · Cited by 178 · cited 1×
“It also binds regulators of histone acetylation and methylatio”
BackgroundCyclin D1 Regulates Cellular Migration through the Inhibition of Thrombospondin 1 and ROCK Signaling
Li, Z., Wang, C., Jiao, X., Lu, Y., Fu, M., Quong, A. A., Dye, C., Yang, J., Dai, M., Ju, X., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02124-05 · Cited by 177 · cited 1×
“Fibroblasts, epithelial cells and macrophages have increased adhesion and reduced migration in the absence of cyclin D1 (REF”
BackgroundDeletion of the p27 Kip1 gene restores normal development in cyclin D1-deficient mice
Geng, Y., Yu, Q., Sicińska, E., Das, M., Bronson, R. T., & Siciński, P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.194 · Cited by 174 · cited 1×
“Similarly, deletion of the gene encoding p27 ( Cdkn1b ) can rescue many of the developmental defects that are observed following the deletion of Ccnd1 or Cdk4 (REF”
BackgroundErtel, A., Dean, J. L., Rui, H., Liu, C., Witkiewicz, A., Knudsen, K. E., & Knudsen, E. S. (2010) · Cell Cycle · doi:10.4161/cc.9.20.13454 · Cited by 173
Stendahl, M., Kronblad, Å., Rydén, L., Emdin, S., Bengtsson, N. O., & Landberg, G. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601831 · Cited by 169
Cyclins: Roles in mitogenic signaling and oncogenic transformation
Musgrove, E. A. (2006) · Growth Factors · doi:10.1080/08977190500361812 · Cited by 168
Self-citationJohnson, S. M., Torrice, C. D., Bell, J. F., Monahan, K. B., Jiang, Q., Wang, Y., Ramsey, M. R., Jin, J., Wong, K.-K., Su, L., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41402 · Cited by 168 · cited 1×
“Although it has been suggested that CDK4/CDK6 inhibitors could be used to induce reversible quiescence, thereby protecting normal cells from radiation-induced toxicit”
BackgroundIdentification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1
Benzeno, S., Lu, F., Guo, M., Barbash, O., Zhang, F., Herman, J. G., Klein, P. S., Rustgi, A. K., & Diehl, J. A. (2006) · Oncogene · doi:10.1038/sj.onc.1209644 · Cited by 167
Zhong, Z., Yeow, W.-S., Zou, C., Wassell, R., Wang, C., Pestell, R. G., Quong, J. N., & Quong, A. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-08-1108 · Cited by 166
Reis-Filho, J. S., Savage, K., Lambros, M. B. K., James, M., Steele, D., Jones, R. L., & Dowsett, M. (2006) · Modern Pathology · doi:10.1038/modpathol.3800621 · Cited by 163
The activities of cyclin D1 that drive tumorigenesis
Ewen, M. E., & Lamb, J. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.02.005 · Cited by 162 · cited 1×
“However, it is also possible that some of the non-catalytic functions of cyclin D1 contribute to its role in human cance”
BackgroundThe role of cell cycle regulatory proteins in the pathogenesis of melanoma
Li, W., Sanki, A., Karim, R. Z., Thompson, J. F., Lee, C. S., Zhuang, L., McCarthy, S. W., & Scolyer, R. A. (2006) · Pathology · doi:10.1080/00313020600817951 · Cited by 158
Ball, K. L., Laín, S., Fåhræus, R., Smythe, C., & Lane, D. P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00029-7 · Cited by 157
Elsheikh, S. E., Green, A. R., Aleskandarany, M. A., Grainge, M. J., Paish, C. E., Lambros, M. B. K., Reis-Filho, J. S., & Ellis, I. O. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9659-8 · Cited by 154 · cited 1×
“However, cyclin D1 expression did not correlate with survival in another study, although this study did find that CCND1 amplification was a significant independent predictor of surviva”
BackgroundRen, J., Wang, Y., Liang, Y., Zhang, Y., Bao, S., & Xu, Z. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.103911 · Cited by 152 · cited 1×
“and ribosome biogenesis (through phosphorylation of MEP50, a co-activator of the arginine methyltransferase PRMT5, which in turn methylates ribosome proteins”
BackgroundMarzec, M., Kasprzycka, M., Lai, R. L., Gladden, A. B., Wlodarski, P. K., Tomczak, E. Z., Nowell̀, P. C., DePrimo, S. E., Sadis, S., Eck, S., et al. (2006) · Blood · doi:10.1182/blood-2006-04-016634 · Cited by 149
Alternative Cyclin D1 Splice Forms Differentially Regulate the DNA Damage Response
Li, Z., Jiao, X., Wang, C., Shirley, L. A., Elsaleh, H., Dahl, O., Wang, M., Soutoglou, E., Knudsen, E. S., & Pestell, R. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0312 · Cited by 143
Acquired radioresistance of human tumor cells by DNA-PK/AKT/GSK3β-mediated cyclin D1 overexpression
Shimura, T., Kakuda, S., Ochiai, Y., Nakagawa, H., Kuwahara, Y., Takai, Y., Kobayashi, J., Komatsu, K., & Fukumoto, M. (2010) · Oncogene · doi:10.1038/onc.2010.238 · Cited by 143 · cited 1×
“It has also been implicated in acquired radioresistanc”
BackgroundBarbash, O., Zamfirova, P., Lin, D. I., Chen, X., Yang, K., Nakagawa, H., Lu, F., Rustgi, A. K., & Diehl, J. A. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.017 · Cited by 140
Jeselsohn, R. M., Brown, N. E., Arendt, L. M., Klebba, I., Hu, M. G., Kuperwasser, C., & Hinds, P. W. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.024 · Cited by 140 · cited 1×
“Although functional mammary glands develop in the absence of CDK4/CDK6 activity, they lack the specific mammary progenitor population that is targeted by ERBB2, pointing to a developmental defect rather than a cell-intrinsic mechanism for the dependence of ERBB2-driven mammary oncogenesis on the CDK activation functio…”
BackgroundMatsubayashi, H., Sato, N., Fukushima, N., Yeo, C. J., Walter, K., Brune, K. A., Şahin, F., Hruban, R. H., & Goggins, M. (2003) · PubMed · Cited by 140
Cyclin D1 Induction of Cellular Migration Requires p27KIP1
Li, Z., Jiao, X., Wang, C., Ju, X., Lu, Y., Yuan, L., Lisanti, M. P., Katiyar, S., & Pestell, R. G. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1596 · Cited by 139
Cyclin D3 Promotes Adipogenesis through Activation of Peroxisome Proliferator-Activated Receptor γ
Sarruf, D. A., Iankova, I., Abella, A., Assou, S., Miard, S., & Fajas, L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.22.9985-9995.2005 · Cited by 137
Cyclin D1 gene (CCND1) mutations in endometrial cancer
Moreno‐Bueno, G., Rodríguez, S., Sánchez‐Estévez, C., Hardisson, D., Sarrió, D., Prat, J., Cigudosa, J. C., Matías‐Guiu, X., & Palacios, J. (2003) · Oncogene · doi:10.1038/sj.onc.1206868 · Cited by 136
Agarwal, R., Gonzalez-Angulo, A. M., Myhre, S., Carey, M. S., Lee, J., Overgaard, J., Alsner, J., Stemke‐Hale, K., Lluch, A. M., Neve, R. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3293 · Cited by 136 · cited 1×
“, and another large study of 779 breast cancers from multiple cohorts found that although expression of cyclin B1 and cyclin E1 was consistently correlated with Ki67 expression, cyclin D1 expression was no”
ResultWang, L., Wang, J., Blaser, B. W., Duchemin, A.-M., Kusewitt, D. F., Liu, T., Caligiuri, M. A., & Briesewitz, R. (2007) · Blood · doi:10.1182/blood-2007-02-071266 · Cited by 134 · cited 1×
“In vitro resistance to long-term treatment with a CDK4/CDK6-specific inhibitor is associated with increased CDK2 activity in both breast cancer and acute myeloid leukaemia (AML) cell line”
BackgroundCyclin D1-Cdk4 Induce Runx2 Ubiquitination and Degradation
Shen, R., Wang, X., Drissi, H., Liu, F., O’Keefe, R. J., & Chen, D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603439200 · Cited by 132
Aggarwal, P., Lessie, M. D., Lin, D. I., Pontano, L., Gladden, A. B., Nuskey, B., Goradia, A., Wasik, M. A., Klein-Szanto, A. J. P., Rustgi, A. K., et al. (2007) · Genes & Development · doi:10.1101/gad.1586007 · Cited by 132 · cited 1×
“, perhaps acting as a 'safety net' for rapidly proliferating cells, but sustained cyclin D1–CDK4 activity following DNA damage leads to the inappropriate re-replication of DNA and chromosomal damag”
BackgroundCyclin D1 protein expression and gene polymorphism in colorectal cancer
McKay, J., Douglas, J. J., Ross, V. G., Curran, S., Murray, G. I., Cassidy, J., & Initiative, O. B. O. T. A. C. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001001)88:1<77::aid-ijc12>3.0.co;2-o · Cited by 130
Kalish, L. H., Kwong, R. A., Cole, I. E., Gallagher, R. M., Sutherland, R. L., & Musgrove, E. A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0012 · Cited by 129
Self-citationCyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer
Russell, A., Thompson, M., Hendley, J., Trute, L., Armes, J. E., & Germain, D. (1999) · Oncogene · doi:10.1038/sj.onc.1202511 · Cited by 125
A Requirement for Cyclin-Dependent Kinase 6 in Thymocyte Development and Tumorigenesis
Hu, M. G., Deshpande, A., Enos, M., Mao, D., Hinds, E. A., Hu, G., Chang, R., Guo, Z., Dose, M., Mao, C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2473 · Cited by 125 · cited 1×
“The targeted deletion of either Cdk6 or Ccnd3 causes resistance to lymphoma genesi”
BackgroundCyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation
Burd, C. J., Petre, C. E., Morey, L. M., Wang, Y., Revelo, M. P., Haiman, C. A., Lu, S., Fenoglio‐Preiser, C. M., Li, J., Knudsen, E. S., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506281103 · Cited by 125 · cited 1×
“, and although it does bind AR in androgen-dependent prostate cancer cells, it stimulates proliferation, in contrast to the inhibition of androgen-stimulated proliferation by full-length cyclin D1 (REF”
BackgroundCyclin D1 protein expression and gene polymorphism in colorectal cancer
McKay, J., Douglas, J. J., Ross, V. G., Curran, S., Murray, G. I., Cassidy, J., & Initiative, O. B. O. T. A. C. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001001)88:1<58::aid-ijc9>3.0.co;2-q · Cited by 121
Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation.
Padar, A., Sathyanarayana, U. G., Suzuki, M., Maruyama, R., Hsieh, J., Frenkel, E. P., Minna, J. D., & Gazdar, A. F. (2003) · PubMed · Cited by 117
Kornmann, M., Danenberg, K. D., Arber, N., Beger, H. G., Danenberg, P. V., & Korc, M. (1999) · PubMed · Cited by 113
Cell Cycle and Biochemical Effects of PD 0183812
Fry, D. W., Bedford, D. C., Harvey, P. H., Fritsch, A., Keller, P. R., Wu, Z., Dobrusin, E. M., Leopold, W. R., Fattaey, A., & Garrett, M. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008867200 · Cited by 112
The structure of CDK4/cyclin D3 has implications for models of CDK activation
Takaki, T., Echalier, A., Brown, N. R., Hunt, T., Endicott, J. A., & Noble, M. E. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809674106 · Cited by 109 · cited 1×
“The resolution of the cyclin D1–CDK4 and cyclin D3–CDK4 crystal structure”
BackgroundA Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model
Menu, E., García, J., Huang, X., Liberto, M. D., Toogood, P. L., Chen, I., Vanderkerken, K., & Chen‐Kiang, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6404 · Cited by 108 · cited 1×
“CDK4/CDK6 inhibitors may also lead to enhanced efficacy when used in combination with other therapies — for example, the proteasome inhibitor bortezomib or dexamethasone in multiple myelom”
BackgroundDePinto, W., Chu, X., Yin, X., Smith, M., Packman, K. E., Goelzer, P., Lovey, A. J., Chen, Y., Qian, H., Hamid, R., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0355 · Cited by 106
Noel, E. E., Yeste‐Velasco, M., Mao, X., Perry, J., Kudahetti, S. C., Li, N. F., Sharp, S. Y., Chaplin, T., Xue, L., McIntyre, A., et al. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090780 · Cited by 106
Lazaro, J., Bailey, P. J., & Lassar, A. B. (2002) · Genes & Development · doi:10.1101/gad.u-9988r · Cited by 105
Update on the molecular biology of mantle cell lymphoma
Bertoni, F., Rinaldi, A., Zucca, E., & Cavalli, F. (2006) · Hematological Oncology · doi:10.1002/hon.767 · Cited by 103 · cited 1×
“A translocation that juxtaposes CCND1 with the immunoglobulin heavy chain locus ( IGH ), leading to cyclin D1 overexpression, is diagnostic of mantle cell lymphoma (MCL) ( TABLE 1 ), and the small proportion ( CCND2 or CCND3 (REF”
BackgroundCyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy
Rudas, M., Lehnert, M., Huynh, A. T., Jakesz, R., Singer, C., Lax, S., Schippinger, W., Dietze, O., Greil, R., Stiglbauer, W., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4122 · Cited by 102 · cited 1×
“Multiple studies of large cohorts with well-controlled treatment regimens have found a significant association between high cyclin D1 expression and poor outcome in women treated with tamoxife”
BackgroundAdon, A. M., Zeng, X., Harrison, M. K., Sannem, S., Kiyokawa, H., Kaldis, P., & Saavedra, H. I. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00253-09 · Cited by 101 · cited 1×
“Other CDK4 targets have roles in processes that are tightly linked to, and coordinated with, chromosomal DNA replication and segregation, such as centrosome duplication and separatio”
BackgroundCole, A. M., Myant, K., Reed, K. R., Ridgway, R. A., Athineos, D., van den Brink, G. R., Muncan, V., Clevers, H. C., Clarke, A. R., Siciński, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0315 · Cited by 100
Raderschall, E., Bazarov, A., Cao, J., Lurz, R., Smith, A., Mann, W., Ropers, H., Sedivy, J. M., Golub, E. I., Fritz, E., et al. (2002) · Journal of Cell Science · doi:10.1242/jcs.115.1.153 · Cited by 99
Systematic validation of predicted microRNAs for cyclin D1
Jiang, Q., Feng, M., & Mo, Y. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-194 · Cited by 99 · cited 1×
“1, and there are also several other miRNAs that target cyclin D1 (REF”
BackgroundCell-specific responses to loss of cyclin-dependent kinases
Berthet, C., & Kaldis, P. (2007) · Oncogene · doi:10.1038/sj.onc.1210243 · Cited by 97
Cyclin D1 Splice Variants: Polymorphism, Risk, and Isoform-Specific Regulation in Prostate Cancer
Comstock, C. E. S., Augello, M. A., Benito, R. P., Karch, J. M., Tran, T. H., Utama, F. E., Tindall, E. A., Wang, Y., Burd, C. J., Groh, E. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2865 · Cited by 95 · cited 1×
“In other cancers, cyclin D1b is independently overexpresse”
BackgroundSelf-citationMillar, E. K. A., Dean, J. L., McNeil, C. M., O’Toole, S. A., Henshall, S. M., Tran, T. H., Lin, J., Quong, A. A., Comstock, C. E. S., Witkiewicz, A. K., et al. (2009) · Oncogene · doi:10.1038/onc.2009.13 · Cited by 94 · cited 1×
“In other cancers, cyclin D1b is independently overexpresse”
BackgroundSelf-citationNelsen, C. J., Kuriyama, R., Hirsch, B. A., Negron, V. C., Lingle, W. L., Goggin, M. M., Stanley, M. W., & Albrecht, J. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407105200 · Cited by 93
Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells
Sweeney, K. J. E., Swarbrick, A., Sutherland, R. L., & Musgrove, E. A. (1998) · Oncogene · doi:10.1038/sj.onc.1201814 · Cited by 93
Self-citationImpact of differential cyclin D1 expression and localisation in prostate cancer
Comstock, C. E. S., Revelo, M. P., Buncher, C. R., & Knudsen, K. E. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603615 · Cited by 91
Multiple Functions of D-Type Cyclins Can Antagonize pRb-Mediated Suppression of Proliferation
Baker, G. L., Landis, M. W., & Hinds, P. W. (2004) · Cell Cycle · doi:10.4161/cc.4.2.1485 · Cited by 90
Distinct proliferative and transcriptional effects of the D-type cyclins in vivo
Mullany, L. K., White, P., Hanse, E. A., Nelsen, C. J., Goggin, M. M., Mullany, J. E., Anttila, C. K., Greenbaum, L. E., Kaestner, K. H., & Albrecht, J. H. (2008) · Cell Cycle · doi:10.4161/cc.7.14.6274 · Cited by 85
Zeng, X., Shaikh, F. Y., Harrison, M. K., Adon, A. M., Trimboli, A. J., Carroll, K. A., Sharma, N., Timmers, C. D., Chodosh, L. A., Leone, G. W., et al. (2010) · Oncogene · doi:10.1038/onc.2010.253 · Cited by 84
Cyclin D3/CDK11p58 Complex Is Involved in the Repression of Androgen Receptor
Zong, H., Chi, Y., Wang, Y., Yang, Y., Zhang, L., Chen, H., Jiang, J., Li, Z., Hong, Y., Wang, H., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01753-06 · Cited by 82 · cited 1×
“Both direct cyclin D3–AR binding and cyclin D3–CDK11 phosphorylation of AR have been implicated in these effect”
BackgroundPontano, L. L., Aggarwal, P., Barbash, O., Brown, E. J., Bassing, C. H., & Diehl, J. A. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01085-08 · Cited by 81 · cited 1×
“Nuclear cyclin D1 (but not cyclin D2) is rapidly degraded after DNA damage or replication stress as part of the S phase DNA damage checkpoin”
BackgroundYang, C., Trent, S., Ionescu-Tiba, V., Lan, L., Shioda, T., Sgroi, D. C., & Schmidt, E. V. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1645 · Cited by 78
Šarčević, B., Lilischkis, R., & Sutherland, R. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.52.33327 · Cited by 77
Self-citationZhang, L., Fried, F. B., Guo, H. W., & Friedman, A. D. (2007) · Blood · doi:10.1182/blood-2007-08-109702 · Cited by 73
Negative Regulation of TSC1-TSC2 by Mammalian D-Type Cyclins
Zacharek, S. J., Xiong, Y., & Shumway, S. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2236 · Cited by 72 · cited 1×
“Cyclin D–CDK4 regulation of cell growth occurs through effects on both protein synthesis (through tuberous sclerosis complex (TSC) regulation of mTOR”
BackgroundHaddad, R. I., Weinstein, L. J., Wieczorek, T. J., Bhattacharya, N., Raftopoulos, H., Oster, M. W., Zhang, X., Latham, V. M., Costello, R., Faucher, J., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0229 · Cited by 72
Tan, A. R., Yang, X., Berman, A. W., Zhai, S., Sparreboom, A., Parr, A. L., Chow, C., Brahim, J. S., Steinberg, S. M., Figg, W. D., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0025 · Cited by 72
Yasui, M., Yamamoto, H., Ngan, C. Y., Damdinsuren, B., Sugita, Y., Fukunaga, H., Gu, J., Maeda, M., Takemasa, I., Ikeda, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1213 · Cited by 67 · cited 1×
“These consequences include angiogenesis, through the regulation of vascular endothelial growth factor (VEGF) expressio”
BackgroundDesign of a Novel Class of Peptide Inhibitors of Cyclin-dependent Kinase/Cyclin Activation
Gondeau, C., Gerbal‐Chaloin, S., Bello, P. A., Aldrian, G., Morris, M. C., & Divita, G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413690200 · Cited by 67
Pabalan, N., Bapat, B. V., Sung, L., Jarjanazi, H., Francisco-Pabalan, O., & Özçelik, H. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0169 · Cited by 67
Expression and subcellular localization of cyclin D1 protein in epithelial ovarian tumour cells
Dhar, K. K., Branigan, K., Parkes, J., Howells, R. E. J., Hand, P., Musgrove, C., Strange, R. C., Fryer, A. A., Redman, C. W. E., & Hoban, P. R. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690826 · Cited by 65
DNA Replication Stalling Attenuates Tyrosine Kinase Signaling to Suppress S Phase Progression
Shields, B. J., Hauser, C., Bukczynska, P. E., Court, N. W., & Tiganis, T. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.06.003 · Cited by 64 · cited 1×
“, perhaps acting as a 'safety net' for rapidly proliferating cells, but sustained cyclin D1–CDK4 activity following DNA damage leads to the inappropriate re-replication of DNA and chromosomal damag”
BackgroundBexarotene and Erlotinib for Aerodigestive Tract Cancer
Dragnev, K. H., Petty, W. J., Shah, S. J., Biddle, A., Desai, N. B., Memoli, V. A., Rigas, J. R., & Dmitrovsky, E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.9521 · Cited by 63 · cited 1×
“In a well-studied example, the RXR activator bexarotene enhances the effects of the EGFR inhibitor erlotinib in lung cancer, and this is thought to be due to the cooperative repression of cyclin D1 expressio”
BackgroundAlternate Cyclin D1 mRNA Splicing Modulates p27KIP1 Binding and Cell Migration
Li, Z., Wang, C., Jiao, X., Katiyar, S., Casimiro, M. C., Prendergast, G. C., Powell, M. J., & Pestell, R. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706992200 · Cited by 62 · cited 1×
“It also has a more potent transforming ability than full-length cyclin D1, perhaps because high levels of cyclin D1b do not trigger a DNA damage respons”
BackgroundSiemeister, G., Luecking, U., Wagner, C., Detjen, K. M., Coy, C. M., & Bosslet, K. (2006) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2006.06.003 · Cited by 62
Nakajima, K., Inagawa, M., Uchida, C., Okada, K., Tane, S., Kojima, M., Kubota, M., Noda, M., Ogawa, S., Shirato, H., et al. (2011) · Development · doi:10.1242/dev.059295 · Cited by 61 · cited 2×
“CCND1: IGH translocation t(11;14)(q13;q32) Multiple myeloma 16% 185”
BackgroundDespouy, G., Bastie, J.-N., Deshaies, S., Balitrand, N., Mazharian, A., Rochette‐Egly, C., Chomienne, C., & Delva, L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210697200 · Cited by 59 · cited 1×
“Cyclin D3 interacts with cellular retinoic acid-binding protein 2 (CRABP2) and retinoic acid receptor-α (RARα); it is the only D-cyclin to interact with these protein”
BackgroundCyclin D1 in low-dose radiation-induced adaptive resistance
Ahmed, K. M., Fan, M., Nantajit, D., Cao, N., & Li, J. J. (2008) · Oncogene · doi:10.1038/onc.2008.265 · Cited by 56 · cited 1×
“Cytoplasmic cyclin D1 inhibits apoptosis following low-level DNA damag”
BackgroundDragnev, K. H., Ma, T., Cyrus, J., Galimberti, F., Memoli, V. A., Busch, A. M., Tsongalis, G. J., Seltzer, M., Johnstone, D. W., Erkmen, C. P., et al. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0376 · Cited by 56
Canela-Canela, N., Orzáez, M., Fucho, R., Mateo, F., Gallego, R. G., Pineda‐Lucena, A., Bachs, O., & Pérez‐Payá, E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603511200 · Cited by 55
Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells
Kehn‐Hall, K., Berro, R., Alhaj, A., Bottazzi, M. E., Yeh, W.-I., Klase, Z. A., Duyne, R. V., Fu, S. W., & Kashanchi, F. (2007) · Oncogene · doi:10.1038/sj.onc.1210319 · Cited by 53
Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance
Waltersson, M. A., Nordenskjöld, B. A., Rutqvist, L. E., Skoog, L. K., & Stål, O. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-6457-4 · Cited by 52
Molecular alterations associated with cyclin d1 overexpression in endometrial cancer
Moreno‐Bueno, G., Rodríguez, S., Sánchez‐Estévez, C., Marcos, R., Hardisson, D., Cigudosa, J. C., & Palacios, J. (2004) · International Journal of Cancer · doi:10.1002/ijc.20130 · Cited by 49
The Role of the Cyclin D1-Dependent Kinases in ErbB2-Mediated Breast Cancer
Yang, C., Ionescu-Tiba, V., Burns, K. L., Gadd, M. A., Zukerberg, L. R., Louis, D. N., Sgroi, D. C., & Schmidt, E. V. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63190-2 · Cited by 48 · cited 1×
“The CDK activation function of cyclin D1 is largely dispensible during mammary development, but it is required for mammary oncogenesis, as mice lacking cyclin D1 or CDK4, or expressing the CDK4/CDK6-specific inhibitor INK4A or the cyclin D1 K112E mutant, are resistant to mammary cancers induced by ERBB2 (also known as…”
BackgroundBagella, L., Sun, A., Tonini, T., Abbadessa, G., Cottone, G., Paggi, M. G., Luca, A. D., Claudio, P. P., & Giordano, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209987 · Cited by 47
Hanse, E. A., Nelsen, C. J., Goggin, M. M., Anttila, C. K., Mullany, L. K., Berthet, C., Kaldis, P., Crary, G. S., Kuriyama, R., & Albrecht, J. H. (2009) · Cell Cycle · doi:10.4161/cc.8.17.9465 · Cited by 45
Abramson, V. G., Troxel, A. B., Feldman, M. D., Mies, C., Wang, Y., Sherman, L. S., McNally, S., Diehl, J. A., & DeMichele, A. M. (2010) · PubMed · Cited by 39
Somatic variation and cancer: therapies lost in the mix
Biankin, A. V., & Hudson, T. J. (2011) · Human Genetics · doi:10.1007/s00439-011-1010-0 · Cited by 39 · cited 1×
“Whole-genome transcript profiling and sequencing efforts have documented numerous distinct molecular phenotypes, often accounting for”
BackgroundLi, R., An, S., Chen, Z. H., Zhang, G.-C., Zhu, J.-Q., Nie, Q., Xie, Z., Guo, A., Mok, T. S. K., & Wu, Y.-L. L. C. (2008) · Human Pathology · doi:10.1016/j.humpath.2008.05.008 · Cited by 37 · cited 1×
“In some cancers, such as lung cancer, cyclin D1b is coordinately overexpressed with full-length cyclin D1, although the absolute expression level of cyclin D1b is much lowe”
BackgroundCyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy
Wang, M., Sun, L., Qian, J., Han, X., Zhang, L., Lin, P., Cai, Z., & Yi, Q. (2009) · Leukemia · doi:10.1038/leu.2009.19 · Cited by 37
Sanchez, G., Delattre, O., Auboeuf, D., & Dutertre, M. (2008) · Cell Cycle · doi:10.4161/cc.6445 · Cited by 36
Kim, C. J., Nishi, K., Isono, T., Okuyama, Y., Tambe, Y., Okada, Y., & Inoue, H. (2009) · Molecular Carcinogenesis · doi:10.1002/mc.20547 · Cited by 35 · cited 1×
“It also has a more potent transforming ability than full-length cyclin D1, perhaps because high levels of cyclin D1b do not trigger a DNA damage respons”
BackgroundScott, E. N., Thomas, A., Molife, L. R., Ahmed, S. I., Blagden, S. P., Fong, P. C. C., Kowal, K., McCoy, C., Wiesinger, H., Steward, W. P., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0968-y · Cited by 34
Diab, S., Eckhardt, S. G., Tan, A. R., Frenette, G., Gore, L., DePinto, W., Grippo, J. F., DeMario, M., Mikulski, S. M., & Papadimitrakopoulou, S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3528 · Cited by 29
Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer
Schiewer, M. J., Morey, L. M., Burd, C. J., Liu, Y., Merry, D. E., Ho, S., & Knudsen, K. E. (2008) · Oncogene · doi:10.1038/onc.2008.446 · Cited by 29 · cited 1×
“Conversely, mimetics of the domain of cyclin D1 involved in AR repression ( BOX 1 ) have been proposed as a therapeutic approach in androgen-dependent prostate cance”
BackgroundBerkofsky‐Fessler, W., Nguyen, T. Q., Delmar, P., Molnos, J., Kanwal, C., DePinto, W., Rosinski, J., McLoughlin, P., Ritland, S., DeMario, M., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0083 · Cited by 25
Wu, W.-H., Slomovitz, B. M., Soliman, P. T., Schmeler, K., Celestino, J., Milam, M. R., & Lu, K. H. (2006) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2006.00642.x · Cited by 23
A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991
O'Dwyer, P. J., LoRusso, P. M., DeMichele, A., Gupta, V., Barbi, A., Dials, H. J., Chen, I., Courtney, R., Wilner, K. D., & Schwartz, G. K. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3550 · Cited by 20
Cyclin D1 suppresses retinoblastoma protein-mediated inhibition of TAFII250 kinase activity
Siegert, J. L., Rushton, J. J., Sellers, W. R., Kaelin, W. G., & Robbins, P. D. (2000) · Oncogene · doi:10.1038/sj.onc.1203966 · Cited by 20
Locatelli, G., Bosotti, R., Ciomei, M., Brasca, M. G., Calogero, R., Mercurio, C., Fiorentini, F., Bertolotti, M., Scacheri, E., Scaburri, A., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1163 · Cited by 17
Tissue Microarray Analysis of Cyclin D1 Gene Amplification and Gain in Colorectal Carcinomas
Toncheva, D. I., Petrova, D. T., Tzenova, V., Dimova, I. I., Yankova, R., Yordanov, V., Damjanov, D., Todorov, T., & Zaharieva, B. M. (2004) · Tumor Biology · doi:10.1159/000081097 · Cited by 17
Cotargeting Cyclin D1 Starts a New Chapter in Lung Cancer Prevention and Therapy
Kim, E. S., Lee, J. J., & Wistuba, I. I. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0143 · Cited by 17
Role of Cdk4 in lymphocyte function and allergen response
Chow, Y. H., Zhu, X. D., Liu, L., Schwartz, B. R., Huang, X. Z., Harlan, J. M., & Schnapp, L. M. (2010) · Cell Cycle · doi:10.4161/cc.9.24.14209 · Cited by 15
Kuo, T. C., Chavarría‐Smith, J., Huang, D. Y., & Schlissel, M. S. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01349-10 · Cited by 15
Frazier (2009) · International Journal of Oncology · doi:10.3892/ijo_00000473 · Cited by 13
Cirstea, D. D., Hideshima, T., Pozzi, S., Vallet, S., Ikeda, H., Santo, L., Loferer, H., Vaghela, N., Okawa, Y., Perrone, G., et al. (2008) · Blood · doi:10.1182/blood.v112.11.2759.2759 · Cited by 13
Oxindole Inhibitors of Cyclin-Dependent Kinases as Anti-Tumor Agents
Smith, P. J., & Yue, E. W. (2006) · CRC Press eBooks · doi:10.1201/9781420005400-20 · Cited by 5
Siemeister, G., Lücking, U., Wengner, A. M., Lienau, P., Schatz, C. A., Mumberg, D., & Ziegelbauer, K. B. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-3883 · Cited by 3
Cited by
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
“Cyclin D2 (CCND2) is deregulated in many human cancers, including MM (Bergsagel et al., 2005; Musgrove et al., 2011).”
BackgroundPalbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Emerging landscape of oncogenic signatures across human cancers
Ciriello, G., Miller, M. L., Aksoy, B. A., Senbabaoglu, Y., Schultz, N., & Sander, C. (2013) · Nature Genetics · doi:10.1038/ng.2762 · Cited by 1,378
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
“Although several lines of evidence argue for CDK4/6-independent roles of D-type cyclins as transcriptional cofactors for HRs (68) and”
Metadata
- Authors
- Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L.
- Affiliations
- Garvan Institute of Medical Research (AU)
- Corresponding author
- Sutherland, Robert L.
- ORCID
- Caldon, C. Elizabeth
- Venue
- Nature Reviews Cancer
- Published
- 2011-07-07
- Volume
- 11
- Issue
- 8
- Pages
- 558-572
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2089655089
- Cited by
- 1,370
- References
- 190
- Citations by year
- 2026: 54 · 2025: 65 · 2024: 57 · 2023: 78 · 2022: 85 · 2021: 102 · 2020: 113 · 2019: 100 · 2018: 93 · 2017: 130 · 2016: 129 · 2015: 105 · 2014: 92 · 2013: 91 · 2012: 75
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- cyclin D1, cyclin D, cyclin-dependent kinases, CDK4, CDK6, oncogene deregulation, cancer therapy, therapeutic target, biomarkers, patient subgroup identification, tumor progression
- MeSH terms
- Humans, Neoplasms, Oncogenes, Polymorphism, Genetic, Cyclin D
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.